Compare Quest Diagnostics Inc (DGX) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Moody's Corporation — how do they compare? Quest Diagnostics Inc trades at $238.15 (market cap $26.21B), while Moody's Corporation trades at $477.7 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 3.1× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | MCO | |
|---|---|---|
Market Cap | $26.21B | $82.52B |
Sector | Health | Financials |
52-Week High | $238.50 | $539.61 |
52-Week Low | $173.49 | $412.23 |
Enterprise Value | $31.97B | $88.54B |
Dividend Yield | 1.45% | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Moody's Corporation (MCO) trades at $478.14, showing modest daily gains of 0.08%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust profitability metrics, including 34.25% net income margin and 80.15% ROE. Recent Q2 2026 results exceeded expectations with $4.68 EPS versus $4.26 expected, driven by strong analytics demand and debt issuance activity. Technical indicators remain neutral with support at $475 and resistance at $481.
MCO presents a compelling growth story with premium valuation justified by exceptional profitability and market leadership. The primary investment opportunity lies in sustained analytics growth and credit rating dominance, while risks include valuation sensitivity and potential debt market volatility. Analyst consensus remains bullish with $561.88 price target representing 17.5% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
